Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VERTEX PHARMACEUTICALS

(VRTX)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-30 pm EDT
312.16 USD   -0.66%
03/27Vertex, CRISPR Sign Licensing Deal to Back Development of Vertex's Diabetes Treatment
MT
03/27Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
BU
03/21Insider Sell: Vertex Pharmaceuticals
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex: Q4 Earnings Snapshot

02/07/2023 | 05:55pm EDT

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Tuesday reported fourth-quarter earnings of $818.9 million.

On a per-share basis, the Boston-based company said it had net income of $3.15. Earnings, adjusted for stock option expense and pretax expenses, were $3.76 per share.

The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of $3.53 per share.

The drugmaker posted revenue of $2.3 billion in the period, also exceeding Street forecasts. Eleven analysts surveyed by Zacks expected $2.29 billion.

For the year, the company reported profit of $3.32 billion, or $12.82 per share. Revenue was reported as $8.93 billion.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VRTX at https://www.zacks.com/ap/VRTX

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights., source Associated Press News

All news about VERTEX PHARMACEUTICALS
03/27Vertex, CRISPR Sign Licensing Deal to Back Development of Vertex's Diabetes Treatment
MT
03/27Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development o..
BU
03/21Insider Sell: Vertex Pharmaceuticals
MT
03/21Bernstein Initiates Vertex Pharmaceuticals at Outperform With $344 Price Target
MT
03/20Insider Sell: Vertex Pharmaceuticals
MT
03/17MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
AQ
03/17Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2..
AQ
03/16Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2..
BU
03/16Vertex Pharmaceuticals Incorporated Announces Publication in New England Journal of Med..
CI
03/14Insider Sell: Vertex Pharmaceuticals
MT
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2023 9 710 M - -
Net income 2023 3 377 M - -
Net cash 2023 14 381 M - -
P/E ratio 2023 24,1x
Yield 2023 -
Capitalization 80 254 M 80 254 M -
EV / Sales 2023 6,78x
EV / Sales 2024 6,00x
Nbr of Employees 4 800
Free-Float 99,7%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 312,16 $
Average target price 334,11 $
Spread / Average Target 7,03%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS8.10%80 788
REGENERON PHARMACEUTICALS, INC.13.56%87 446
WUXI APPTEC CO., LTD.0.60%34 168
BIONTECH SE-18.14%29 635
GENMAB A/S-11.80%24 611
BEIGENE, LTD.0.82%23 148
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer